One of these immune checkpoint–targeted agents, pembrolizumab, which targets PD-1, a negative co-stimulatory receptor and a strong inhibitor of T-cell response, is under clinical trial for treatment of HCC [40]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.